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ABSTRACT
Background: Nanotechnology-based bioassays that detect the presence and/or absence of a combination of cell
markers are increasingly used to identify stem or progenitor cells, assess cell heterogeneity, and evaluate tumor
malignancy and/or chemoresistance. Delivery methods that enable nanoparticles to rapidly detect emerging,
intracellular markers within cell clusters of biopsies will greatly aid in tumor characterization, analysis of functional
state and development of treatment regimens.
Results: Experiments utilized the Sendai virus to achieve in vitro, cytosolic delivery of Quantum dots in cells
cultured from Human brain tumors. Using fluorescence microscopy and Transmission Electron Microscopy, in vitro
experiments illustrated that these virus-based liposomes decreased the amount of non-specifically endocytosed
nanoparticles by 50% in the Human glioblastoma and medulloblastoma samples studied. Significantly, virus-based
liposome delivery also facilitated targeted binding of Quantum dots to cytosolic Epidermal Growth Factor Receptor
within cultured cells, focal to the early detection and characterization of malignant brain tumors.
Conclusions: These findings are the first to utilize the Sendai virus to achieve cytosolic, targeted intracellular
binding of Qdots within Human brain tumor cells. The results are significant to the continued applicability of
nanoparticles used for the molecular labeling of cancer cells to determine tumor heterogeneity, grade, and
chemotherapeutic resistivity.
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Background
Nanoparticles have facilitated unprecedented study of
biological processes and molecular markers within a vari-
ety of cell samples (reviewed in [1-4]). Diagnostic assays
where nanoparticles are used to detect the presence and/
or absence of a combination of cell markers are becom-
ing increasingly significant in the identification of pro-
genitor or stem-like cells found within a variety of
tumors [5]. While nanotechnology has pioneered major
advances in cancer detection, diagnosis, and treatment
[6], tumors within brain continue to pose one of the low-
est survival rates five years after diagnosis [7]. While such
poor prognosis is largely associated with the highly inva-
sive nature of malignant brain tumors [8-10], the cellular
heterogeneity of diseased brain also plays a large role, as
constituent subpopulations of neoplastic cells with stem-
like properties [11] appear to be resistant to conventional
radiotherapy and chemotherapeutic regimens [12]. Emer-
ging studies have underscored the significance of intra-
cellular markers when identifying neoplastic stem-like
populations (reviewed in [13]), either in tandem with
existing extracellular markers (e.g. CD133, PAX6,
reviewed in [14]) or alone. Numerous cytosolic molecules
currently serve as therapeutic targets for radiosensitiza-
tion, including heat shock proteins [15], binding proteins
[16], Hypoxia Inducible Factors HIF1 and HIF2 [17],
transcription factors [18], and phospholipoases [19]. In
addition, recent studies point to cytosolic markers as
excellent detectors of biochemical signatures from cells
previously thought to evade the neural system, such as
the prion-like protein Doppel (Dpl) found in the male
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t e i n sa n dc l a s sI I Ib-tubulin found in bone marrow-
derived mesenchymanl stem cells [21].
Labeling of intracellular molecules is notoriously diffi-
cult to achieve using nanoparticles because of the highly
esoteric selectivity required [22]. Intracellular delivery of
nanoparticles is strongly affected by both the nature of
the particle and the type of cell examined (reviewed in
[23]). For example, established delivery methods of bio-
conjugates, such as Quantum dots (Qdots), via endocy-
tosis, pinocytosis and injection are known to alter cell
function as well as exhibit varied effectiveness per cell
type and/or experimental condition [24,25]. Further,
alternative approaches such as electroporation [26],
nanoneedles [27], and cell-penetrating peptides [28]
have led to internalized Qdots that can become trapped
within the endocytic pathway and/or form large aggre-
gates in the cytoplasm [29]. Most recently, researchers
have utilized cell penetrating peptides [30,31], pH-
dependent fusogenic peptides [32], as well as logic-
embedded vectors [33] to achieve endosomal release
after internalization. Others have minimized endosomal
trapping by using silica [34], gold [35,36], and polymer-
based nanoparticles [37] and polyactic acid [38], while
yet others have disrupted endocytosis by using light-
activated disruption of intracellular vesicles [39], or con-
trolled sub-cellular damage of endosomal structures
[40].
Recent applications have revived the practice of nano-
particle encapsulation by incorporating nanoparticles
within patented synthetic proteins and polymers, as well
as within antiretroviral complexes [41], each with a varying
degree of endosomal escape. Our group has previously
shown that cationic liposomes are able to facilitate intra-
cellular delivery of Qdots within live brain cancer cells
[42], but demonstrated that the method is cell line-depen-
dent: Liposomal delivery of Qdots was cytoplasmic within
glioblastoma-derived cells, but resulted in endocytosis and
trapping of liposomes within endosomes when HeLa cells
were used. More unconventional approaches to nanoparti-
cle delivery have begun to incorporate viruses previously
used to deliver other nanosized molecules, such as DNA,
synthetic oligonucleotides, and pharmaceuticals [43]. Chy-
meric bacteriophages have been employed to target
tumors and introduce intracellular agents bound to its sur-
face [44], while the plant mosaic virus [45] was used to
incorporate Qdots coated with various molecules (e.g.
streptavidin-biotin, dihydrolipoic acid) within its capsid.
A recent study adapted the simian virus 40 capsid to
encapsulate Qdots functionalized with different surface
coatings (e.g. DNA, PEG) for transport within kidney cells
[46]. While delivery was successful, it remained unclear
whether the virus itself enabled cytosolic release of Qdots
or if the Qdots remained trapped within cellular compart-
ments [46].
The current study has achieved cytoplasmic delivery of
targeted Qdots via chimeric fusions between the Sendai
virus and cationic liposomes [ 4 7 ] .T h eS e n d a iv i r u si sa
mouse parainfluenza virus that has been safely used for
over two decades, in vitro and in vivo, to deliver molecules
such as plasmid DNAs, siRNAs, proteins, iron particles,
and pharmaceuticals into numerous cell types (reviewed in
[48]). Its role as a delivery vector capitalizes on two types
of proteins present in its capsid: (i) Hemagglutinating and
Neuraminidase (HN) proteins, used for attachment of the
virus to neuraminic acid-containing receptors on host
cells, hemagglutination of erythrocytes, and neuraminidase
activity [49]; and (ii) Fusion (F) proteins needed for virus
penetration of host cell membranes, virus-induced hemo-
lysis, and cell fusion [49-51]. In this work we use the Sen-
dai virus to generate virus-based liposomes that achieve
cytosolic delivery of targeted Qdots into live Human brain
tumor cells with high, consistent efficiency. Qdots were
functionalized with a monoclonal biotinylated antibody
(Ab) designed to specifically recognize an intracellular epi-
tope of the Epidermal Growth Factor Receptor (EGFR).
EGFR was chosen as a candidate target protein because its
over-expression and up-regulation is recognized as a sig-
nificant step in the pathogenesis and progression of a wide
variety of cancers, including tumors of the brain [52-55].
Further, previous work from our laboratory has success-
fully labeled activated EGFR populations in live brain can-
cer cells by binding Qdots to the extracellular domain of
EGFR and then inducing receptor activation to detect
intracellular, activated EGFR [56]. In the current study,
delivery of Qdot by chimeric fusions between the Sendai
virus and cationic liposomes, henceforth called virus-based
liposomes (VBLs), was assessed using three different
Human cancer cell types: (i) Medulloblastoma (MB), the
most common form of pediatric brain tumor; (ii) Glioblas-
toma (GBM), the most common form of tumor in adult
brain; and (iii) HeLa cervical cancer, a well-studied cell
line used here as an experimental control.
Results and Discussion
Cellular EGFR Localization in Medulloblastoma
In order to examine the targeted delivery of nanoparticles
to cytosolic EGFR targets in MB, experiments first exam-
ined EGFR in MB cells during signaling events, with and
without ligand stimulation. EGFR signaling is known to be
tightly regulated by receptor endocytosis and lysosome-
mediated degradation [57]. In adult brain, the tumor sup-
pressor gene, Mig-6, has been recently shown to quell the
malignant potential of GBM and dampen EGFR signaling
by driving EGFR into late endosomes and lysosome-
mediated degradation upon ligand stimulation [58].
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MB cells delineates a poorer outcome, and is believed to
be a function of MB type and grade [52]. Early detection
of such signaling is highly significant for MB patient prog-
nosis, as 70% of children with elevated levels of EGFR
expression succumb to their neoplastic disorder prior to 4
years of age [52].
Our first set of experiments examined EGFR localization
within MB-derived cells by labeling the receptor with an
antibody that recognizes the intracellular amino-acid
sequence 985-996 of EFGR, henceforth referred to as
iEGFR. This domain was chosen for experiments of tar-
geted delivery so that Qdot binding would have minimal
effects on EGFR phosphorylation and its subsequent
recruitment of signaling adaptor proteins (see Methods).
EGFR location was determined both by standard immu-
nostaining using secondary fluorescence Alexa 488 detec-
tion (Figure 1A), as well as via nanoparticle complexes
formed between biotinylated iEFGR Abs and Qdots
(Figure 2B). Measured co-localizations of the receptor
with the endocytic pathway via confocal microscopy
(Figure 1A) illustrated that 43.1% +/- 4.4% of EGFR was
present within the endosomes of non-ligand stimulated
MB cells when measured via conventional secondary anti-
bodies, consistent with 36.2% +/- 0.4% endosomal pre-
sence when measured via Qdots (Figure 1C).
These initial results are not only among the first to
utilize Qdots to measure the cytosolic EGFR population
in MB, but additionally depict the EGFR population
internalized within the endocytic compartments of these
cells in the absence of tyrosine kinase activity [59].
These findings become critical to nanoparticle labeling
of EGFR within MB, as increased endosomal EGFR
signaling is being explored as a marker of de-differen-
tiated cells that are linked to recurrence and radioresis-
tivity in malignant brain tumors [52].
Nanoparticle Cytosolic Delivery via Liposome-only and
Virus-Based Liposomes
Researchers have recently illustrated that nanoparticles
conjugated to a drug or antibody cannot simply be inter-
nalized in order to bind cytosolic or endosomal targets,
because the nanocomplexes can distinctly alter cellular
processes at the molecular level [60]. As a result, the next
set of experiments utilized VBLs to facilitate Qdot binding
to cytosolic iEGFR in order to derive measurements of
both the populations of native cytosolic EGFR and endo-
somal EGFR within MB samples. Here, we examined the
in vitro, intracellular delivery of Qdots targeted to iEGFR
via cationic liposomes alone, and by using VBLs. (Note
that experiments do not seek to track the translocation of
cytosolic EGFR proteins to endosomes during signaling).
As shown in the schematics of Figure 2, when liposomes
are used for intracellular delivery (Figure 2A1), Qdots can
become internalized non-specifically within endocytic
compartments (Figure 2A2) and remain trapped within
liposomes, which are themselves trapped within the endo-
cytic compartments of the cell (Figure 2A3). By contrast,
when VBLs are used for intracellular delivery (Figure 2B1),
functionalized Qdots can be released within the cytosol
(Figure 2B2) and remain free to bind to their targets (Fig-
ure 2B3). A schematic of how the VBLs were generated
(Figure 2C) helps to illustrate how VBLs can be selective
for intracellular targeting. The cartoon includes TEM
images of an inactivated virus (approximately 200 nm in
diameter) as well as of a liposome (approximately 100 nm
Figure 1 Immunostaining of intracellular EGFR in medulloblastoma. A. Labeling of EGFR using an antibody that recognizes an internal
isotope, iEFGR (Alexa 488; green), and of the endocytic pathway using Transferrin (Tf) (purple) in medulloblastoma (MB) cells; B. Labeling of
EGFR in MB using Qdots functionalized with biotinylated iEFGR (purple) and of the endocytic pathway using Tf (green); C. Percentage co-
localization between Tf and iEGFR Ab, and Tf and Qdot:iEGFR Ab complexes. Nuclei are indicated by the letter “N”. Scale bar equals 50 μmi n
both confocal images.
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Page 3 of 9Figure 2 Schematics of nanoparticle delivery using liposomes-only and virus-based liposomes. A. Intracellular delivery of Qdots
functionalized with biotinylated antibodies for iEFGR by using liposomes-only. Liposomes containing functionalized Qdots are incubated with
the cells (A1). The liposomes are internalized via endocytosis by the cells (A2). Liposomes are internalized within cell endosomes, trapping the
functionalized Qdots (A3); B. Intracellular delivery of Qdots functionalized with biotinylated antibodies for iEFGR by using virus-based liposomes
(VBLs). VBLs containing functionalized Qdots are incubated with the cells (B1). VBLs fuse with the plasma membrane to release Qdots into the
cytosol (B2). The functionalized Qdots bind to their intracellular targets on the EGFR (B3). C. Preparation of VBLs: Sendai viruses (1) were
inactivated by exposure to UV light (2) (for details see Methods). A TEM insert illustrates an inactivated virus of ~ 200 nm diameter. Liposomes
containing targeted Qdots (4) were prepared as described in Methods by incorporating Qdots functionalized with anti-iEGFR antibodies into
lipidic membranes (3). A TEM insert illustrates a ~100 nm diameter liposome containing functionalized Qdots. Next, the liposomes were fused
with the inactivated viruses, to give rise to VBLs (5). A TEM insert illustrates the fusion products.
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brane. Experiments used both liposomes-only and VBLs
to deliver non-functionalized Qdots (i.e. without antibody
conjugation) within GBM and HeLa cell samples. Note
that experiments were used to measure the differences in
cytosolic delivery when using VBLs versus liposomes
alone within each cell type, individually. The data is not
compared across different cell lines, which invariably have
different levels of native EGFR expression. In both sam-
ples, the majority of the liposomes containing Qdots were
trapped within endosomes as measured previously by our
laboratory [42,56] using Qdot-Tf co-localization via confo-
cal microscopy: 56% +/- 4.8% for GBM (Figures 3A and
3C), and 80% +/- 3.5% for HeLa (Figures 3D and 3F). Con-
versely, when VBLs were used, Qdots were distributed
sparsely within the cytosol of GBM (Figure 3B) and HeLa
cells (Figure 3E). Measurement of Qdot co-localization
with Tf-labeled endosomes confirmed that 75% +/- 1.9%
of the Qdots were detected intracellularly and outside of
the endosomes for GBM (Figure 3C), leaving only 25% +/-
1.9% trapped in the endosomes. Similarly, 64% +/- 4% of
Qdots were detected outside of the endosomes of HeLa
cells (Figure 3F), while 36% +/- 4% of Qdots were
observed within the endosomes of these cells. Additional
co-localization statistics were performed using Manders
coefficients with values of 0.48 for GBM and 0.81 for
HeLa when liposomes-alone where used with Tf-labeled
endosomes. When VBLs were used with Tf-labeled endo-
somes, Manders coefficient values of 0.72 for GBM and
0.59 for HeLa were tabulated. We note that while the con-
centration of Qdots delivered using liposomes-only
appears higher than the concentration of Qdots delivered
via VBLs, we believe this is due to the higher background
noise of clustered Qdots endocytosed via the liposomes-
only delivery.
Previous studies have utilized nanoparticles for the
detection of markers within breast, prostate and lung
[61,62], but few have examined Qdot applications in
malignant brain tumors [63]. The results of the present
study document an increase of up to 50% in the number
of intracellularly delivered Qdots that remain free to
bind cytosolic targets within malignant brain tumors
when compared to liposomes alone. Such dramatic
increases will augment detection in numerous cancer
diagnostic assays used to characterize the type, grade,
and level of heterogeneity in tumors.
Cytosolic Virus-based Liposome Delivery of Nanoparticles
Targeted to iEGFR
The final set of experiments utilized VBLs to deliver
nanoparticles within live MB samples and to image the
cellular location of the Qdot::iEGFR Ab complexes via
Figure 3 Intracellular delivery of Qdots using liposomes-only and virus-based liposomes in glioblastoma and HeLa cells. Cell nuclei are
denoted by the letter “N” and endocytic pathways are labeled by Transferrin (Tf) (green). Scale bar equals 25 μm in all confocal images. A.
Double labeling of glioblastoma (GBM) cells for non-targeted Qdots delivered by using liposomes-only (purple). B. Double labeling of GBM cells
for non-targeted Qdots delivered by using virus-based liposomes (VBLs) (purple). C. Measurement of Qdot co-localization with endosomes (black)
and cell cytosol (white) when delivered by liposomes-only or VBLs in GBM; D. Double labeling of HeLa cells for non-targeted Qdots delivered by
using liposomes-only (purple). E. Double labeling of HeLa cells for non-targeted Qdots delivered by using VBLs (purple). F. Measurement of Qdot
co-localization with endosomes (black) and cell cytosol (white) when delivered by using liposomes-only and VBLs.
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using liposomes-only as the delivery system, non-func-
tionalized Qdots were detected within Tf-labeled endo-
somes (Figures 4A). Measurement of co-localized
fluorescent signatures revealed that 56% +/- 1.4% of
Qdots were present within the cell endocytic pathway
(Figure 4E). This data indicates that liposomes were pre-
dominantly internalized via endocytosis in MB, as has
been reported for other cell lines (reviewed in [64]).
Moreover, TEM of MB samples treated with liposomes
containing Qdot::iEGFR Ab complexes led to detection
of the well-known electron-dense cores of the Qdots
within the cell endocytic compartments (Figure 4B). In
contrast, when Qdots were delivered using VBLs, confo-
cal microscopy illustrated Qdots that were evenly dis-
tributed throughout the MB cytosol (Figures 4C).
Measured localization of these Qdots revealed that only
30% +/- 3.6% of the Qdot signal was present within the
cell endosomes (Figure 4E). Note that Qdots located
within the endosome are unlikely to bind iEGFR
because they remain trapped within liposomal mem-
branes, as previously shown [42]. However, the data do
illustrate that VBLs released the majority of their cargo
(i.e. 70% +/- 3.7%) into the cytosol of MB cells. Consis-
tent Manders coefficients of 0.68 support this co-locali-
zation. In addition, TEM of the samples treated with
VBLs containing functionalized Qdot::iEFGR Ab com-
plexes illustrated that the Qdots indeed labeled iEGFR
throughout the cells post VBL delivery (Figure 4D).
These novel findings are the first to successfully utilize
VBLs for intracellular, nanoparticle delivery, and also
the first to achieve cytosolic binding of intracellular tar-
gets significant to brain cancer research and detection.
Conclusions
Intracellular delivery of functionalized nanoparticles is a
critical goal for numerous biomedical applications,
especially the early detection and diagnostic of malig-
nant brain tumors. Delivery methods that enable Qdots
to target specific intracellular brain cancer markers will
greatly aid in the molecular labeling of tumor samples
[65,66], as well as in surgical imaging procedures of
brain tumors [67,68]. The current study is the first to
use Sendai virus-based carriers for cytosolic delivery of
targeted nanoparticles, as well as the first to explore
VBLs for the study of intracellular markers in malignant
brain tumors. Results illustrate that VBLs increased the
specific intracellular labeling of EGFR by 50%, and,
importantly, significantly bypassed Qdot entrapment
within endosomes for the GBM and MB brain tumor
samples studied. VBLs provide a reliable and consistent
method for cytosolic delivery of nanoparticles that are
targeted towards highly selective intracellular protein
sequences. Further, virus-based liposomes do not only
facilitate cytosolic delivery, but additionally provide the
feasibility of TEM to enable precise localization of target
proteins.
Methods
Cell Culture
The medulloblastoma-derived Daoy cell line (#HTB-186,
purchased from ATCC, Manassas, VA) was established
from a tumor biopsy of a 4-year-old boy. The glioblas-
toma-derived U251 cells were a kind gift from Dr. Eric
Holland (MSKCC) [55]. The cervical cancer-derived HeLa
cell line (# CCL-2™) was purchased from ATCC, Mana-
ssas, VA. Daoy cells were cultured with sterile EMEM
(Mediatech Inc., Herndon, VA), supplemented with 2% L-
Glutamine (Mediatech Inc., Herndon, VA), 1% Penicillin-
Streptomycin-Amphotericin B - 100× solution (Mediatech
Inc., Herndon, VA), and 10% fetal bovine serum (Gemini
Bio-Products, West Sacramento, CA). U251 and HeLa
cells were cultured with sterile DMEM (Sigma, St. Louis,
MO), supplemented with 1% Penicillin-Streptomycin
Figure 4 Delivery of Qdots, targeted and non-targeted to intracellular EGFR, by using liposomes-only and virus-based liposomes in
medulloblastoma. Nuclei are denoted by the letter “N” and endocytic pathways are labeled by Transferrin (Tf) (green) in all confocal images. A.
Double labeling of medulloblastoma (MB) cells for non-targeted Qdots (purple) delivered by liposomes-only. Scale bar equals 50 μm; B. TEM of
MB cells treated with liposomes-only, which encapsulated Qdots functionalized with biotinylated antibodies for iEFGR (Qdot::iEFGR Ab
complexes). Arrows point to clustered Qdots co-localized with endosomes. Scale bar equals 200 nm; C. Double labeling of MB cells for non-
targeted Qdots (purple) delivered by using virus-based liposomes (VBLs.) Scale bar equals 50 μm; D. TEM of MB cells treated with VBLs that
encapsulated functionalized Qdot::iEFGR Ab complexes. Arrows point to dispersed Qdots. Scale bar equals 200 nm. E. Measurement of Qdot co-
localization with endosomes (black) and with cell cytosol (white) when delivered by liposomes-only or VBLs.
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bovine serum (Thermo Scientific HyClone, Logan, UT).
The cells were grown onto sterile polystyrene tissue cul-
ture flasks (BD Biosciences, Franklin Lakes, NJ) and incu-
bated at 37°C with 5% CO2.
Antibodies and Immunocytochemistry
HeLa, medulloblastoma- and glioblastoma-derived cells
grown on coverslips were fixed with paraformaldehyde
(Sigma, St. Louis, MO) and labeled with biotinylated
mouse antibody for iEFGR (1:500) - recognizing an inter-
nal epitope (Biodesign, Saco, ME), and goat anti-mouse
AlexaFluor
® 488 (Invitrogen Molecular Probes, Eugene,
OR). For the Qdot labeling, a solution of 5 nM streptavi-
din-conjugated Qdot 655 (Invitrogen Molecular Probes,
Eugene, OR)::5 nM iEGFR antibody was incubated on a
shaker for 1 hour at 25°C, and used in the immunocyto-
chemistry after fixing. Transferrin AlexaFluor
® 488 or
594 conjugates (Tf) (Invitrogen Molecular Probes,
Eugene, OR) were used to label the clathrin-mediated
pathway: a 20 μg/mL solution of Tf was applied and
incubated with the cells for 1 hour at 37°C. After labeling,
the cells were subsequently mounted in glycerol (Poly-
science Inc., Warrington, PA). Each experiment was per-
formed three times.
Fluorescence Microscopy and Analysis
Confocal laser scanning microscopy imaging was per-
formed using a Leica TCS SP2 instrument (Leica Micro-
systems, Bannockburn, IL) with a 63× oil immersion
objective (NA 1.4). Identical imaging conditions were used
for each set of experiments. A total of 3-5 samples were
prepared and three random regions were imaged per sam-
ple, three times each per experimental condition. Analysis
of confocal images was performed using Matlab software
(version 7.7.0.471) to import data as matrices containing
absolute intensity values. Data in each matrix was thre-
sholded at 10-15% of the maximum intensity in the
respective matrix in order to eliminate background signal
due to scatter. Co-localization of fluorescent labels was
then defined as the exact overlapping of data points with
values above the threshold value of the respective
matrices. Thresholded Manders Coefficients were also cal-
culated using NIH Image Software (NIH, Bethesda, MA)
to additionally determine co-localization [69].
Liposome Preparation
Cationic lipids were purchased from Avanti Polar Lipids,
Inc. (Alabaster, AL). Two milligrams each of powdered
lipids 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine
(OPPC) and 1, 2 dioleoyl-sn-glycero-3-ethylphosphocho-
line (DOPC+) were dissolved in chloroform at a 1:1
molar ratio in a glass vial. The lipid mixture (1 mg/mL)
was aliquoted into glass vials using a Pasteur pipette
and the vials were placed in a dessicator connected to a
vacuum pump (Neuberger Inc., Trenton, NJ) for 2.5 to
3 hours. Inert nitrogen gas was used afterwards to flush
out the dessicator before opening. The vials containing
lipid sheets were placed at -20°C for at least 24 hours.
The lipid sheets were placed at room temperature prior
to use in order to prevent condensation. The lipid
sheets were hydrated with either of the following two
solutions yielding in both cases liposome solutions with
lipid concentration of 0.5 mg/mL: (i) PBS with 5 nM
streptavidin-conjugated Qdot 655; (ii) PBS with 5 nM
streptavidin-conjugated Qdot 655 functionalized with a
biotinylated antibody for iEFGR (Biodesign, Saco, ME).
The vials were vortexed for four minutes, and then sub-
jected to 3 cycles of freezing at -20°C and thawing at
room temperature. After the last freeze-thaw cycle, the
glass vials containing hydrated liposomes were placed at
room temperature in order to prevent condensation.
The sample was loaded into a 1000 μL gas-tight syringe,
which was placed into an Avanti Mini-Extruder (Avanti
Polar Lipids, Inc., Alabaster, AL). A polycarbonate mem-
brane with a pore diameter size of 200 nm was used for
the extrusion.
Virus-Based Liposome Preparation
The protocol used in this work was a modified version of
the Sendai virus-based protocols found in existing litera-
ture [47]. Briefly, commercial, purified Sendai viruses
(Charles River, Wilmington, MA) were inactivated by
exposure to 9.6 × 105 μJ/cm
2 UV light. Inactivated viruses
were mixed with liposomes prepared as described above at
a ratio of virus: liposomes = 3000 HAU: 1 mg lipid. The
mixture was incubated for 10 minutes on ice to allow the
viruses to dock onto the liposomes, and afterwards 1 hour
at 37°C in a water-bath with shaking (120/min). After this
incubation, the Sendai virus-liposome preparation was
layered over a sucrose gradient (30% sucrose over 60%
sucrose in a 4:1 volume ratio; in PBS), and spun at
approximately 22,000 rpm for 3 hours at 4°C. After spin-
ning, the virus-based liposomes were located in a layer
between the PBS solution and 30% sucrose, while unincor-
porated Sendai virus particles were found between the
30% and 60% sucrose layers. The virus-based liposomes
were generally used immediately after preparation, or were
stored at 4°C for up to 24 hours prior to use.
Liposome- and Virus-Based Liposome Cell Incubation
The liposomes or virus-based liposome solutions, contain-
ing either functionalized or non-targeted Qdots, were
applied directly onto cells plated on coverslips. After
10 minutes incubation on ice to allow the docking of the
delivery system to the cells, cells were incubated at 37°C
for 1 hour. For the intracellular localization of non-
targeted Qdots, cells were also incubated with a 20 μg/mL
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incubation, cells were fixed with 3.7% paraformaldehyde
(Sigma, Atlanta, GA) and mounted in glycerol (Polyscience
Inc., Warrington, PA).
Transmission Electron Microscopy (TEM)
For the analysis of intracellular distribution of Qdots,
medulloblastoma cells cultured on collagen-coated
plates were labeled with Qdot::iEFGR Ab via virus-based
liposome delivery, as described above. After washing
three times with PBS, the cells were fixed with 2% glu-
taraldehyde (Electron Microscopy Services, Hatfield, PA)
for 2 hours at 4°C and then post-fixed with 1% osmium
tetroxide (Electron Microscopy Services, Hatfield, PA)
for 2 hours at 4-8°C. After dehydration by immersing in
serially diluted aqueous ethanol solutions, the specimens
were embedded in epoxy resin, sectioned to 80-100 nm
thick, stained with uranyl acetate, and examined with a
Zeiss EM 902 (Carl Zeiss, Peabody, MA). As a control,
non-targeted Qdots treated cells were also imaged fol-
lowing preparation as described above. A total of 10-15
images per sample were acquired from three different
samples per experimental condition.
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